证券日报网讯 拓新药业8月15日在互动平台回答投资者提问时表示，公司专注于核苷（酸）类医药中间 体及原料药的研发、生产及销售，主要涵盖抗病毒、抗肿瘤和神经系统用药领域。公司的主要产品包括 胞磷胆碱钠、胞磷胆碱、环磷腺苷、盐酸阿糖胞苷、单磷酸阿糖腺苷、利巴韦林、肌苷、阿昔洛韦、胞 嘧啶、5-氟胞嘧啶、胞苷、尿苷等原料药及医药中间体。目前公司未涉及针对基孔肯雅热流行相关的疫 苗和治疗的药物。 （编辑 王雪儿） ...

Market Overview - On August 8, the chemical pharmaceutical sector rose by 0.24% compared to the previous trading day, with Lianhuan Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3635.13, down 0.12%, while the Shenzhen Component Index closed at 11128.67, down 0.26% [1] Stock Performance - Notable declines in individual stocks include: - Shanghai Yizhong: closed at 72.23, down 5.42% with a trading volume of 80,000 shares and a turnover of 573 million yuan - Yifang Bio: closed at 39.80, down 5.37% with a trading volume of 203,000 shares and a turnover of 818 million yuan - Qianhong Pharmaceutical: closed at 10.19, down 4.77% with a trading volume of 1,197,800 shares and a turnover of 1.23 billion yuan [1] Capital Flow Analysis - The chemical pharmaceutical sector experienced a net outflow of 230 million yuan from institutional investors and a net outflow of 93.16 million yuan from retail investors, while retail investors saw a net inflow of 323 million yuan [1] - Key stocks with significant capital flow include: - Meinuohua: net inflow of 236 million yuan from institutional investors, with a 18.01% share - Lianhuan Pharmaceutical: net inflow of 197 million yuan from institutional investors, with a 13.40% share [2] - Other notable stocks include Han Yu Pharmaceutical and Bo Rui Pharmaceutical, with net inflows of 171 million yuan and 131 million yuan from institutional investors, respectively [2]

证券日报网讯拓新药业7月29日在互动平台回答投资者提问时表示，截至2025年7月18日，公司股东户数 20，864户。 （文章来源：证券日报） ...

证券代码：301089 证券简称：拓新药业 公告编号：2025-035 拓新药业集团股份有限公司 关于持股5%以上股东变更名称的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或者重大遗漏。 特此公告。 拓新药业集团股份有限公司 董事会 2025年7月25日 拓新药业集团股份有限公司（以下简称"公司"）近日收到公司持股5%以上 股东SHENGLIN HOLDING CO.LTD.（中文名：咸氏投资有限公司）的通知，其名称 由"SHENGLIN HOLDING CO.LTD."变更为"1461565 ONTARIO INC.（中文名：1461565 安大略省公司）"，现已完成工商变更登记，并于近日在中国证券登记结算有限 责任公司完成证券账户名称变更。变更后的工商登记信息如下： 名称：1461565 ONTARIO INC. 安大略省公司编号：1461565 注册地址：170 Sheppard Ave E.,Unit 600,North York,Ontario, M2N 3A4,Canada 法定代表人：YINGMIN XU（徐英敏） 成立日期：2001年1月30日 截 ...

Core Viewpoint - The strategic investment by Tuoxin Pharmaceutical in Jinsan Biotechnology highlights the growing optimism in the anti-aging market, particularly in the industrialization of ergothioneine, a rare amino acid with significant health benefits [1][6][20]. Group 1: Strategic Transformation of Tuoxin Pharmaceutical - Tuoxin Pharmaceutical, established in 2001, has evolved into a benchmark enterprise in the nucleoside raw materials sector, focusing on the development of nutritional enhancers and health products [2][4]. - The company aims to deepen its core areas while expanding into the health sector, particularly in nutritional enhancers and health foods, to create new growth points [4][20]. Group 2: Jinsan Biotechnology's Technological Breakthroughs - Jinsan Biotechnology has achieved a significant milestone by producing ergothioneine with a purity of 99.99% and a monthly production capacity of 3-5 tons, drastically reducing raw material costs by 90% [6][8]. - The company has established a cGMP production standard platform, enabling it to surpass industry standards in ergothioneine purity [8][11]. Group 3: Clinical Research and Market Expansion - Jinsan Biotechnology has expanded the application of ergothioneine beyond traditional skincare to areas such as eye health, sleep health, and liver health, with several clinical studies underway [10][11]. - The company has seen a 428-fold increase in search popularity for its ergothioneine products on Xiaohongshu, indicating strong market demand [11][20]. Group 4: Industry Impact and Global Opportunities - The collaboration between Tuoxin Pharmaceutical and Jinsan Biotechnology signifies a transformative shift in China's biopharmaceutical landscape, moving from treatment-focused approaches to preventive health and wellness [17][20]. - Jinsan Biotechnology's involvement in setting industry standards and obtaining international certifications positions it as a leader in the global health market [18][20].

Group 1 - The core point of the article is that Tuoxin Pharmaceutical has invested 10 million yuan in Jiangsu Jinsan Biotechnology Co., Ltd., acquiring a 1.75% stake, which will enhance its capabilities in the health sector [1][3] - The investment agreement stipulates that the funds will be used solely for the development and operation of Jinsan Biotechnology's main business [1] - Tuoxin Pharmaceutical is actively expanding into the health sector, developing nutritional supplements, food additives, and health foods, with successful mass production of certain functional foods [1][2] Group 2 - In 2024, Tuoxin Pharmaceutical has focused on "technological innovation, dynamic product structure optimization, and deep integration of the industrial chain" to address core business fluctuations and cultivate new growth points [2] - The company has established multiple technology platforms, including chemical synthesis and synthetic biology, and has improved the conversion of R&D results [2] - Tuoxin Pharmaceutical plans to accelerate the R&D and registration of health products over the next three years, aiming to create a complete commercialization chain [2] Group 3 - Jinsan Biotechnology specializes in the research, production, and application of ergotioneine, with breakthroughs in fermentation and purification technologies [3] - The main products of Jinsan Biotechnology include skincare products, oral capsules, and eye wash solutions [3] - Tuoxin Pharmaceutical's investment in Jinsan Biotechnology is a strategic move to extend its production, sales, and R&D chain, enhancing market competitiveness and profitability [3]

Policy Developments - Shanghai is advancing the standardization research of medical accompaniment services, with a project led by East China Hospital identified as a key research topic for 2024, focusing on service institutions, personnel requirements, service processes, and quality evaluation [2] Drug and Device Approvals - Maike Bio has received a medical device registration certificate for its coagulation factor activity measurement kits, valid from July 8, 2025, to July 7, 2030, aimed at monitoring treatments for coagulation factor deficiencies [3] - Kewang Pharmaceutical's vitamin K1 drops have received a registration acceptance notice from the National Medical Products Administration, intended to prevent vitamin K deficiency bleeding in infants [4] - CanSino has been approved for clinical trials of its trivalent poliovirus vaccine, which is being developed using protein structure design and VLP assembly technology, currently undergoing I/II phase trials in Indonesia [5] Financial Reports - Johnson & Johnson reported Q2 revenue of $23.74 billion, a 5.8% increase year-over-year, exceeding market expectations, with projected annual sales between $93.2 billion and $93.6 billion [6] Capital Markets - Tuoxin Pharmaceutical plans to invest 10 million yuan in Jiangsu Jinsan Biotechnology Co., acquiring a 1.75% stake, with Jinsan successfully producing high-purity ergothioneine for various products [7] - Tsinghua Unigroup's stock auction resulted in the sale of 58.607 million shares, potentially leading to a change in control of the company, with the shares sold at an average price significantly above the latest closing price [8] Industry Events - China National Pharmaceutical Group responded to rumors regarding the "return" of a licensing agreement with Merck for a PD-1/VEGF bispecific antibody, stating that the collaboration is progressing normally and a milestone payment of $300 million is expected upon completion of technology transfer by 2025 [9] Public Sentiment Alerts - A senior executive of Astellas Pharma in China was sentenced to three and a half years in prison for espionage, highlighting potential risks in the pharmaceutical industry [10] Stock Market Alerts - ST Weiming's stock has been placed under risk warning due to a significant price drop and expected losses of 55 million to 85 million yuan for the first half of 2025, leading to a change in its trading name and restrictions on price fluctuations [11]

Group 1 - Henan Province has introduced new policies to support listed companies in mergers and acquisitions, encouraging transformation and resource allocation towards sectors like artificial intelligence, low-altitude economy, biomedicine, new materials, and high-end equipment [1] - Postal Savings Bank announced plans to invest 10 billion yuan to establish a financial asset investment company, marking the establishment of financial asset investment companies by all six major state-owned banks [1] Group 2 - Nvidia CEO Jensen Huang highlighted 11 Chinese companies during his speech at the Chain Expo, praising China's supply chain as a miracle and predicting that factories will be driven by software and AI in the next decade [2] Group 3 - The State Council meeting emphasized strengthening domestic circulation as a strategic move for economic stability, focusing on boosting consumption and optimizing policies to release domestic demand potential [5] - The Minister of Commerce stressed the importance of high-level opening-up to enhance domestic circulation and improve international competitiveness [7] Group 4 - Beijing Yizhuang has launched the first local 6G industry funding support policy, offering up to 30 million yuan for companies undertaking significant 6G technology tasks [9] - National power load has reached a historical high of 1.506 billion kilowatts, marking a 0.55 billion kilowatt increase from last year [10] - China has successfully established the world's first international standard for supercapacitors used in power storage, receiving support from countries like Germany and Japan [10] Group 5 - Fengshen Co. plans to raise up to 1.1 billion yuan through a private placement to expand its production capacity for high-performance giant engineering tires [11] - Pinggao Electric has won a procurement project from the State Grid worth approximately 1.45 billion yuan, accounting for 11.69% of its 2024 revenue [13] - Tuo Xin Pharmaceutical intends to invest 10 million yuan in Jiangsu Jinsan Biotechnology, acquiring a 1.75% stake [15] - Tesla announced the upcoming launch of Model Y L, a luxury electric SUV, expected to be priced around 400,000 yuan [17] - BYD plans the largest-scale OTA update for its "Tian Shen Zhi Yan" intelligent driving system, covering multiple functionalities [19] Group 6 - Wuzhou Zhongda intends to acquire 100% equity of Huzhou South Taihu Technology for 1.457 billion yuan, aiming to enhance its market share in the cogeneration sector [21] - AUX Electric has submitted a listing application to the Hong Kong Stock Exchange, with a market share of 7.1% in 2024 [23] - ST Huawang plans to purchase 55.5% equity of Anhui Niwei Power Systems for a total of approximately 606 million yuan [25] - Shangwei Co. aims to raise up to 1.144 billion yuan through a private placement to enhance its digital transformation and marketing efforts [26] - Faraday Future announced it has secured 105 million USD in financing to accelerate the launch of its new FX Super One model [27] - Huayuan Holdings plans to repurchase shares worth 20 to 40 million yuan for employee stock ownership plans [28] - Pinming Technology expects a net profit of 28 to 34 million yuan for the first half of the year, representing a year-on-year growth of 231.79% to 302.89% [29]

Group 1 - The rumor of Federal Reserve Chairman Powell being fired by Trump caused significant market fluctuations, with a drop in U.S. stocks and a rise in gold and Bitcoin prices [1][3] - After Trump denied the rumors, U.S. stocks rebounded, with the S&P 500 rising by 0.32%, the Dow Jones by 0.53%, and the Nasdaq by 0.26% [1] - The 2-year U.S. Treasury yield fell by over 7 basis points during the rumor but narrowed its decline after the denial [3] Group 2 - Tesla's stock increased by 3.5% as the Model Y L is set to be delivered this fall [2] - Chip stocks experienced mixed results, with AMD rising by 3% while ASML fell by over 8% [2] - The Nasdaq Golden Dragon China Index fell by 1.41%, with notable movements in Chinese concept stocks [2] Group 3 - The U.S. House Financial Services Committee Chairman stated that there are enough votes to push forward a stablecoin bill [5] - The CEO of a major U.S. bank indicated plans to collaborate with some stablecoin projects [6] Group 4 - Major developments in China's economic policies include initiatives to boost consumption and regulate the electric vehicle industry [9][10] - The Henan provincial government has introduced policies to support mergers and acquisitions for listed companies [10] Group 5 - The tungsten market continues to see price increases, with black tungsten concentrate prices rising by 25% since the beginning of the year [21] - The Ministry of Natural Resources has reduced the tungsten mining quota for 2024 and 2023, indicating tighter supply conditions [21] Group 6 - MiniMax is nearing completion of a new financing round of approximately $300 million, with a post-financing valuation exceeding $4 billion [19] - The company is reportedly seeking an A-share listing, reflecting its commercial potential in the AI sector [19] Group 7 - The Beijing Economic Development Zone has launched a special fund to support 6G technology development, with a maximum funding of 30 million yuan for qualifying enterprises [20] - The initiative aims to establish a leading 6G innovation development area by 2030 [20]

Group 1 - Meidi Kai plans to acquire 100% equity of Haisholi and INNOWAVE VIETNAM for a total of 2 billion KRW, entering Samsung's supply chain and filling gaps in its ultra-thin optical film business [3] - Tuo Xin Pharmaceutical will invest 10 million CNY in Jiangsu Jinsan Biotechnology, acquiring a 1.75% stake, as Jinsan has successfully produced high-purity ergothioneine [4] - Zhejiang Energy Power reported a 4.48% increase in power generation to 78.848 billion kWh in the first half of the year, driven by rising electricity demand in Zhejiang province [5] Group 2 - Anker Innovation is researching overseas share issuance to enhance its global strategy and brand image, with no specific plan confirmed yet [6] - *ST Chuangxing announced a change in actual controller to Wang Xiangrong after a judicial auction of shares [7] - Hosheng Silicon Industry's controlling shareholder plans to transfer 5.08% of its shares for 2.634 billion CNY [8] Group 3 - Wuchan Zhongda's subsidiary plans to acquire 100% equity of South Taihu Technology for 1.457 billion CNY, aiming to strengthen its position in the cogeneration sector [9] - Postal Savings Bank intends to invest 10 billion CNY to establish a financial asset investment company, supporting technological innovation and private enterprises [10] - *ST Huawang plans to purchase 55.5% equity of Niwei Power for a total of approximately 6.01 billion CNY, focusing on the development of high-pressure fuel tank systems for hybrid vehicles [11] Group 4 - Tiande Yu expects a 50.89% increase in net profit to 152 million CNY in the first half of 2025, driven by growth in display driver chips [14] - Pinming Technology anticipates a net profit increase of 231.79% to 340 million CNY in the first half of 2025, attributed to growth in construction information software [15] - *ST Jinglun forecasts a loss of 19 to 22 million CNY in the first half of 2025, despite a 23.5% revenue increase [16] Group 5 - Jindi Co. signed an industrial project investment contract with the government for no less than 1.5 billion CNY to expand its market in Southwest China [17] - Baiyun Electric is expected to win a procurement project from the State Grid worth 164 million CNY [18] Group 6 - Fulei New Materials plans to reduce its stake by up to 1.33% through trading [19] - Yaxin Security's shareholders plan to collectively reduce their stake by up to 3% [20] - Zhongchong Co.'s controlling shareholder plans to reduce its stake by up to 1.5% [21] Group 7 - Huayuan Holdings intends to repurchase shares worth 20 to 40 million CNY for employee stock ownership plans [24] - Taiji Group plans to repurchase shares worth 80 to 120 million CNY, all for cancellation [25] Group 8 - Fengshen Co. plans to raise up to 1.1 billion CNY through a private placement for a tire expansion project [26] - Shangwei Co. plans to raise up to 1.144 billion CNY through a private placement to enhance its capabilities [27] - Shanggao Environmental plans to raise up to 718 million CNY through a private placement for working capital and debt repayment [28]